HomeAI · summaries
Storia in 10 fonti
Samsung Biologics lançará oferta de US$ 1,8 bilhão pela suíça PolyPeptide
A aquisição ampliará a capacidade da empresa sul-coreana na produção de terapias baseadas em peptídeos, incluindo medicamentos GLP-1 para tratamento de obesidade e diabetes
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
swissinfo.ch
Samsung Biologics to Buy PolyPeptide in $1.8 Billion Deal
(Bloomberg) -- Samsung Biologics Co. agreed to acquire Switzerland’s PolyPeptide Group AG in an all-cash deal that values the contract drugmaker’s equity at about 1.46 billion…
- ·
cnbc.com
Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal
South Korea's Samsung Biologics said on Monday that it had made an all-cash bid of 1.46 billion Swiss francs ($1.8 billion) for Switzerland's PolyPeptide Group.
